Two studies analyzing the effect of a recent drug known as "BG-12", for treating multiple sclerosis, have shown up with positive results. The drug has been found potential enough to help avoiding relapsing.

The latest study trails for the drug were reported to be in their Phase III, which is the closest step to attain approval for the drug and collect more information relating to the safety and potential of the drug.

National Multiple Sclerosis Society affirmed that each week more than 200 residents of US are diagnosed with the condition. During the condition, body's own immune system attacks the central nervous system.

Sysmptoms associated with the condition maybe mild, ranging from no sensation in the limbs to acute sysmptoms, including disability, vision loss and even paralysis.

According to the society, majority of the sufferers of the condition are diagnosed aged between 20 and 50.

Further, it explained that MS is broadly classified under four categories, relapsing-remitting MS, 85% of the sufferers are reported to be at first suffering from this type.

The findings in the studies have raised hopes that soon there would a new treatment to treat the disease, which has affected an estimated 400,000 people in United States alone.

Biogen Idec manufactured drug currently is seeking approval from FDA.